The epigenetic mechanisms involved in the treatment resistance of glioblastoma

Abstract

Glioblastoma (GBM) is an aggressive malignant brain tumor with almost inevitable recurrence despite multimodal management with surgical resection and radio-chemotherapy. While several genetic, proteomic, cellular, and anatomic factors interplay to drive recurrence and promote treatment resistance, the epigenetic component remains among the most versatile and heterogeneous of these factors. Herein, the epigenetic landscape of GBM refers to a myriad of modifications and processes that can alter gene expression without altering the genetic code of cancer cells. These processes encompass DNA methylation, histone modification, chromatin remodeling, and non-coding RNA molecules, all of which have been found to be implicated in augmenting the tumor’s aggressive behavior and driving its resistance to therapeutics. This review aims to delve into the underlying interactions that mediate this role for each of these epigenetic components. Further, it discusses the two-way relationship between epigenetic modifications and tumor heterogeneity and plasticity, which are crucial to effectively treat GBM. Finally, we build on the previous characterization of epigenetic modifications and interactions to explore specific targets that have been investigated for the development of promising therapeutic agents.

Keywords

DNA methylation / epigenetics / glioblastoma / histone modification / miRNA / treatment resistance / tumoral heterogeneity

References

[1] Ostrom QT,Neff C.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020.Neuro Oncol2023;25:iv1-iv99

[2] Torrisi F,Denaro S.Epigenetics and metabolism reprogramming interplay into glioblastoma: novel insights on immunosuppressive mechanisms.Antioxidants2023;12:220 PMCID:PMC9952003

[3] Rezaee A,Tirabadi FJ.Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: function of non-coding RNAs.Biomed Pharmacother2023;165:115187

[4] Ghannad-Zadeh K,Wu M.One-carbon-mediated purine synthesis underlies temozolomide resistance in glioblastoma.Cell Death Dis2024;15:774 PMCID:PMC11511812

[5] Pervjakova N,Morris AP.Imprinted genes and imprinting control regions show predominant intermediate methylation in adult somatic tissues.Epigenomics2016;8:789-99 PMCID:PMC5066126

[6] van Eijk KR,Boks MP.Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects.BMC Genomics2012;13:636 PMCID:PMC3583143

[7] Maunakea AK,Bilenky M.Conserved role of intragenic DNA methylation in regulating alternative promoters.Nature2010;466:253-7 PMCID:PMC3998662

[8] Karpf AR.Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells.Cancer Res2005;65:8635-9

[9] Guo JU,Shin JH.Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain.Nat Neurosci2014;17:215-22 PMCID:PMC3970219

[10] Schaffner SL,Hentrich T,Kobor MS.Distinct impacts of alpha-synuclein overexpression on the hippocampal epigenome of mice in standard and enriched environments.Neurobiol Dis2023;186:106274

[11] Perzel Mandell KA,Wilton R.Genome-wide sequencing-based identification of methylation quantitative trait loci and their role in schizophrenia risk.Nat Commun2021;12:5251 PMCID:PMC8413445

[12] Lorente A,Urdangarín E.RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.Brain Pathol2009;19:279-92

[13] Shukla S,Thinagararjan S.A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.Cancer Res2013;73:6563-73

[14] Liang WW,Jayasinghe RG.Clinical Proteomic Tumor Analysis ConsortiumIntegrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.Cancer Cell2023;41:1567-1585.e7

[15] Carlos-Escalante JA,Soto-Reyes E.Deep DNA sequencing of MGMT, TP53 and AGT in mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.J Neurooncol2023;161:165-74

[16] Zhou J,Zhao J.Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.Cancer Biol Med2023;20:385-400 PMCID:PMC10246439

[17] Barciszewska AM,Głodowicz P,Naskręt-Barciszewska MZ.A new epigenetic mechanism of temozolomide action in glioma cells.PLoS One2015;10:e0136669 PMCID:PMC4550362

[18] Sareen H,Becker TM,de Souza P.Molecular biomarkers in glioblastoma: a systematic review and meta-analysis.Int J Mol Sci2022;23:8835 PMCID:PMC9408540

[19] Chen X,Gan H.A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.Nat Commun2018;9:2949 PMCID:PMC6063898

[20] Shin YJ,Lee Y.PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma.J Exp Med2019;216:1120-34

[21] Singh SK,Habib A.TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro.Front Oncol2023;13:1279806 PMCID:PMC10597663

[22] Wiencke JK,Jelluma N.Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.Neuro Oncol2007;9:271-9 PMCID:PMC1907411

[23] Brun M,Monckton EA.Nuclear factor I represses the notch effector HEY1 in glioblastoma.Neoplasia2018;20:1023-37 PMCID:PMC6138789

[24] Li Q,Ma X,Zhou L.POFUT1 acts as a tumor promoter in glioblastoma by enhancing the activation of notch signaling.J Bioenerg Biomembr2021;53:621-32

[25] Kopan R.The canonical notch signaling pathway: unfolding the activation mechanism.Cell2009;137:216-33 PMCID:PMC2827930

[26] Bazzoni R.Role of notch signaling pathway in glioblastoma pathogenesis.Cancers2019;11:292 PMCID:PMC6468848

[27] Saito N,Hirai N.Effect of notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.Brain Tumor Pathol2015;32:176-83

[28] Yu JB,Zhan RY.Aberrant notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion.Mol Med Rep2016;14:1263-8

[29] Wang Y,Geng R.Notch intracellular domain regulates glioblastoma proliferation through the notch1 signaling pathway.Oncol Lett2021;21:303 PMCID:PMC7905607

[30] Tsung AJ,Asuthkar S.Methylation regulates HEY1 expression in glioblastoma.Oncotarget2017;8:44398-409 PMCID:PMC5546488

[31] Götze S,Reifenberger G,Sievers S.Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas.Int J Cancer2010;126:2584-93

[32] Lambiv WL,Delorenzi M.The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.Neuro Oncol2011;13:736-47 PMCID:PMC3129269

[33] Horiguchi K,Tosaka M.Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.Oncogene2003;22:7862-5

[34] Jayaram H,Jain SU.S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3.Proc Natl Acad Sci U S A2016;113:6182-7

[35] Wilson JR.Determination of histone methyltransferase structure by crystallography. In: margueron R, Holoch D, editors. Histone methyltransferases. New York: Springer US; 2022. pp. 137-47.

[36] Chinot OL,Fuentes S.Correlation between O⁶-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.J Clin Oncol2007;25:1470-5

[37] Zhang J,Han L.EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.Cancer Lett2015;356:929-36

[38] Vinchure OS,Tabasum S.Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.Int J Cancer2019;145:1254-69

[39] Yin Y,Li X,Xu Y.EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.J Neuroinflammation2017;14:220 PMCID:PMC5684749

[40] McCornack C,Hardi A,Kim AH.The function of histone methylation and acetylation regulators in GBM pathophysiology.Front Oncol2023;13:1144184 PMCID:PMC10185819

[41] Weiss VH,Soriano MA,Silver PA.The structure and oligomerization of the yeast arginine methyltransferase, Hmt1.Nat Struct Biol2000;7:1165-71

[42] Fischle W,Jacobs SA,Allis CD.Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by polycomb and HP1 chromodomains.Genes Dev2003;17:1870-81 PMCID:PMC196235

[43] Blanc RS.Arginine methylation: the coming of age.Mol Cell2017;65:8-24

[44] Walport LJ,Chowdhury R.Arginine demethylation is catalysed by a subset of JmjC histone lysine demethylases.Nat Commun2016;7:11974 PMCID:PMC4931022

[45] Farrelly LA,Zhao S.Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3.Nature2019;567:535-9

[46] Young D,Sidoli S.The role of histone H3 lysine demethylases in glioblastoma.Cancer Metastasis Rev2023;42:445-54

[47] Ye L,Wang Y.Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.CNS Neurosci Ther2024;30:e14649

[48] Schneider J,Johnson FC,Shilatifard A.Rtt109 is required for proper H3K56 acetylation: a chromatin mark associated with the elongating RNA polymerase II.J Biol Chem2006;281:37270-4

[49] Schuettengruber B,Iovino N.Trithorax group proteins: switching genes on and keeping them active.Nat Rev Mol Cell Biol2011;12:799-814

[50] Gallo M,Coutinho FJ.A tumorigenic MLL-homeobox network in human glioblastoma stem cells.Cancer Res2013;73:417-27

[51] Kim E,Woo DH.Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.Cancer Cell2013;23:839-52 PMCID:PMC4109796

[52] Chen YN,Jiang R,Cheng CD.EZH2 is a potential prognostic predictor of glioma.J Cell Mol Med2021;25:925-36 PMCID:PMC7812280

[53] Zhang Y,Chen L,Feng S.EZH2 overexpression is associated with poor prognosis in patients with glioma.Oncotarget2017;8:565-73 PMCID:PMC5352178

[54] Suvà ML,Janiszewska M.EZH2 is essential for glioblastoma cancer stem cell maintenance.Cancer Res2009;69:9211-8

[55] Fan TY,Xiang P.et al.Int J Clin Exp Pathol2014;7:6662-70 PMCID:PMC4230130

[56] Yue Q,Shen Y.Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-mediated MLH1 intron retention.Adv Sci2024;11:e2309290

[57] Kaur E,Ghorai A.Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.Neuro Oncol2020;22:1785-96

[58] Venneti S.Metabolic modulation of epigenetics in gliomas.Brain Pathol2013;23:217-21 PMCID:PMC3615671

[59] Shankar SR,Rao VK,Ow JR.G9a, a multipotent regulator of gene expression.Epigenetics2013;8:16-22 PMCID:PMC3549875

[60] Tao H,Su Y.Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.Mol Cell Biochem2014;394:23-30

[61] Bao L,Lai HT.Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration.Nucleic Acids Res2018;46:6576-91 PMCID:PMC6061882

[62] Melcher M,Aagaard L,Laible G.Structure-function analysis of SUV39H1 reveals a dominant role in heterochromatin organization, chromosome segregation, and mitotic progression.Mol Cell Biol2000;20:3728-41 PMCID:PMC85674

[63] Schultz DC,Negorev D,Rauscher FJ 3rd.SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins.Genes Dev2002;16:919-32 PMCID:PMC152359

[64] Spyropoulou A,Dalagiorgou G.Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation.Neuromolecular Med2014;16:70-82

[65] Sepsa A,Gargalionis A.Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.PLoS One2015;10:e0115101 PMCID:PMC4300227

[66] Feoli A,Cipriano A.Identification of a protein arginine methyltransferase 7 (PRMT7)/protein arginine methyltransferase 9 (PRMT9) inhibitor.J Med Chem2023;66:13665-83

[67] Husmann D.Histone lysine methyltransferases in biology and disease.Nat Struct Mol Biol2019;26:880-9 PMCID:PMC6951022

[68] Li XX,Su WJ.The role of KDM4A-mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis.Kaohsiung J Med Sci2024;40:161-74

[69] Zhong C,Li X.HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis.Cell Death Dis2022;13:160 PMCID:PMC8857186

[70] Wang L,Zhou Y,Hu K.Up-regulation of miR-663a inhibits the cancer stem cell-like properties of glioma via repressing the KDM2A-mediated TGF-β/SMAD signaling pathway.Cell Cycle2021;20:1935-52 PMCID:PMC8565824

[71] Liau BB,Donohue LK.Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance.Cell Stem Cell2017;20:233-246.e7 PMCID:PMC5291795

[72] Banasavadi-Siddegowda YK,An M.PRMT5 as a druggable target for glioblastoma therapy.Neuro Oncol2018;20:753-63 PMCID:PMC5961180

[73] Han X,Zhang W.Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.J Neurooncol2014;118:61-72 PMCID:PMC4076054

[74] Holmes B,Saunders JT.The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.J Neurooncol2019;145:11-22 PMCID:PMC6776692

[75] Wang S,Yang B.The role of protein arginine-methyltransferase 1 in gliomagenesis.BMB Rep2012;45:470-5

[76] Banasavadi-Siddegowda YK,Frair E.PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.Oncogene2017;36:263-74

[77] Sachamitr P,Ciamponi FE.PRMT5 inhibition disrupts splicing and stemness in glioblastoma.Nat Commun2021;12:979 PMCID:PMC7881162

[78] Liao Y,Lin Y.PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism.Cell Death Dis2022;13:943 PMCID:PMC9646854

[79] Kim YZ.Altered histone modifications in gliomas.Brain Tumor Res Treat2014;2:7-21 PMCID:PMC4049557

[80] Kouzarides T.Chromatin modifications and their function.Cell2007;128:693-705

[81] Shabane PS.Significant compaction of H4 histone tail upon charge neutralization by acetylation and its mimics, possible effects on chromatin structure.J Mol Biol2021;433:166683 PMCID:PMC8608375

[82] Lv D,Hou Y.Histone acetyltransferase KAT6A upregulates PI3K/AKT signaling through TRIM24 binding.Cancer Res2017;77:6190-201 PMCID:PMC5690809

[83] Vakoc CR,Wang H.Profile of histone lysine methylation across transcribed mammalian chromatin.Mol Cell Biol2006;26:9185-95 PMCID:PMC1698537

[84] Dali-Youcef N,Moussallieh FM.Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and ¹H-HRMAS metabolomic profile in human gliomas.Sci Rep2015;5:9087

[85] Li S,Mao L.Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.Brain Res2018;1692:154-62

[86] Diss E,Nguyen D,Kwok Y.Vorinostat(SAHA) promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells.J Clin Oncol Res2014;2 PMCID:PMC4219415

[87] Kim JH,Kim IH.Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.Int J Radiat Oncol Biol Phys2004;59:1174-80

[88] Li ZY,Chen L.Histone deacetylase inhibitor RGFP109 overcomes temozolomide resistance by blocking NF-κB-dependent transcription in glioblastoma cell lines.Neurochem Res2016;41:3192-205

[89] Das ND,Hon CC.Defining super-enhancers by highly ranked histone H4 multi-acetylation levels identifies transcription factors associated with glioblastoma stem-like properties.BMC Genomics2023;24:574 PMCID:PMC10523799

[90] Tao Z,Wang H.BRD4 regulates self-renewal ability and tumorigenicity of glioma-initiating cells by enrichment in the notch1 promoter region.Clin Transl Med2020;10:e181

[91] Flaus A,Barton GJ.Identification of multiple distinct Snf2 subfamilies with conserved structural motifs.Nucleic Acids Res2006;34:2887-905 PMCID:PMC1474054

[92] Grüne T,Eberharter A.Crystal structure and functional analysis of a nucleosome recognition module of the remodeling factor ISWI.Mol Cell2003;12:449-60

[93] Tran HG,Iyer VR.The chromo domain protein chd1p from budding yeast is an ATP-dependent chromatin-modifying factor.EMBO J2000;19:2323-31 PMCID:PMC384354

[94] Schubert HL,Kasten MM.Structure of an actin-related subcomplex of the SWI/SNF chromatin remodeler.Proc Natl Acad Sci U S A2013;110:3345-50 PMCID:PMC3587198

[95] Chen K,Sia Y.Mechanism of action of the SWI/SNF family complexes.Nucleus2023;14:2165604 PMCID:PMC9839376

[96] Di Giuseppe F,Pallini R.Changes induced by P2X7 receptor stimulation of human glioblastoma stem cells in the proteome of extracellular vesicles isolated from their secretome.Cells2024;13:571 PMCID:PMC11011151

[97] Hodges C,Crabtree GR.The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer.Cold Spring Harb Perspect Med2016;6:a026930 PMCID:PMC4968166

[98] Ganguly D,Cai C,Pfeffer LM.Chromatin remodeling factor BRG1 regulates stemness and chemosensitivity of glioma initiating cells.Stem Cells2018;36:1804-15 PMCID:PMC7427091

[99] Ji J,Zhang X.Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ.Cell Death Dis2018;9:517 PMCID:PMC5938705

[100] Yang C,Wang Y.Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma.J Cell Mol Med2023;27:2770-81

[101] Zhang B,Cobb GP.microRNAs as oncogenes and tumor suppressors.Dev Biol2007;302:1-12

[102] ParvizHamidi M,Ostadrahimi S.Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform.Biotechnol Appl Biochem2019;66:261-5

[103] Wang Q,Li A.Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma.J Exp Clin Cancer Res2012;31:97 PMCID:PMC3554474

[104] Mekala JR,Chamarthy S.Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.Metab Brain Dis2023;38:1801-29 PMCID:PMC10227410

[105] Hombach S.Non-coding RNAs: Classification, biology and functioning. In: Slaby O, Calin GA, editors. Non-coding RNAs in colorectal cancer. Cham: Springer International Publishing; 2016. pp. 3-17.

[106] Sato K,Fujiwara K.miRNA218 targets multiple oncogenes and is a therapeutic target for osteosarcoma.Oncol Rep2022;47:92 PMCID:PMC8968766

[107] Castro-Muñoz LJ,Sahlgren C,De La Cruz-Hernández E.Modulating epigenetic modifications for cancer therapy (review).Oncol Rep2023;49:59 PMCID:PMC9942256

[108] Wang Z,Li Q,Ma J.LncRNA DLGAP1-AS1 accelerates glioblastoma cell proliferation through targeting miR-515-5p/ROCK1/NFE2L1 axis and activating Wnt signaling pathway.Brain Behav2021;11:e2321

[109] Zheng Q,Guo W.Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs.Nat Commun2016;7:11215 PMCID:PMC4823868

[110] Sun J,Zhang J.Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2 : MiR-152-3p regulate glioma cell apoptosis and invasion.J Exp Clin Cancer Res2017;36:100 PMCID:PMC5539621

[111] Xiao S,Qiu X.miR-29c contribute to glioma cells temozolomide sensitivity by targeting O⁶-methylguanine-DNA methyltransferases indirectely.Oncotarget2016;7:50229-38

[112] Gu X,Shen L.MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A.Am J Transl Res2018;10:2834-47

[113] Du W,Wei K.MiR-10b-5p impairs TET2-mediated inhibition of PD-L1 transcription thus promoting immune evasion and tumor progression in glioblastoma.Tohoku J Exp Med2023;260:205-14

[114] Han L,Jiang Y,Tang L.SNHG29 regulates miR-223-3p/CTNND1 axis to promote glioblastoma progression via Wnt/β-catenin signaling pathway.Cancer Cell Int2019;19:345 PMCID:PMC6924063

[115] Li L,Zou SC,Chen ZC.MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44.J Neurooncol2019;141:19-30

[116] Subaiea GM,Afsar S.Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: therapeutic challenges and opportunities.Pathol Res Pract2024;253:155022

[117] Chen H,Fei X,Jiang D.miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1.Tumour Biol2016;37:6761-8

[118] Munoz JL,Rameshwar P.High expression of miR-9 in CD133⁺ glioblastoma cells in chemoresistance to temozolomide.J Cancer Stem Cell Res2015;3:e1003 PMCID:PMC4917210

[119] Chen G,Zhao H.MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.J Cell Mol Med2020;24:5363-74

[120] Munoz JL,Mareedu S.Cycling quiescence in temozolomide resistant glioblastoma cells is partly explained by microRNA-93 and -193-mediated decrease of cyclin D.Front Pharmacol2019;10:134 PMCID:PMC6395452

[121] Ren S.AC016405.3, a novel long noncoding RNA, acts as a tumor suppressor through modulation of TET2 by microRNA-19a-5p sponging in glioblastoma.Cancer Sci2019;110:1621-32 PMCID:PMC6500966

[122] Ahmadov U,Bartl J.The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma.Cell Death Dis2021;12:885 PMCID:PMC8478910

[123] Wu AC,Chang KY.HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells.J Exp Clin Cancer Res2022;41:47

[124] Wu P,Chen Q.Lnc-TALC promotes O⁶-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p.Nat Commun2019;10:2045

[125] Lu C,Wang X.DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.Mol Cancer2020;19:28 PMCID:PMC7011291

[126] Patel AP,Trombetta JJ.Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.Science2014;344:1396-401 PMCID:PMC4123637

[127] Yabo YA,Golebiewska A.Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma.Neuro Oncol2022;24:669-82 PMCID:PMC9071273

[128] Roy-Camille R,Gagna G.Malignant bone tumors and giant cell tumors of the sacrum in adults.Rev Chir Orthop Reparatrice Appar Mot1987;73:82-91

[129] Safa AR,Cohen-Gadol AA,Bijangi-Vishehsaraei K.Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs.Genes Dis2015;2:152-63 PMCID:PMC4484766

[130] Lauko A,Ahluwalia MS.Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors.Semin Cancer Biol2022;82:162-75 PMCID:PMC9618157

[131] Gill BJ,Malone HR.MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.Proc Natl Acad Sci U S A2014;111:12550-5 PMCID:PMC4151734

[132] Bhat KPL,Vaillant B.Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.Cancer Cell2013;24:331-46 PMCID:PMC3817560

[133] Heddleston JM,McLendon RE,Rich JN.The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.Cell Cycle2009;8:3274-84 PMCID:PMC2825672

[134] McCoy MG,Hung CK.Endothelial cells promote 3D invasion of GBM by IL-8-dependent induction of cancer stem cell properties.Sci Rep2019;9:9069 PMCID:PMC6588602

[135] Bhutta BS,Berim I. Hypoxia. In: StatPearls. Treasure Island (FL): 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482316/. [Last accessed on 21 Dec 2024]

[136] Chinnaiyan P,Potthast L.Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.Neuro Oncol2012;14:93-100 PMCID:PMC3246000

[137] Krauze AV,Chang MG.A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma.Int J Radiat Oncol Biol Phys2015;92:986-92 PMCID:PMC4510472

[138] Turcan S,Borodovsky A.Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor decitabine.Oncotarget2013;4:1729-36 PMCID:PMC3858559

[139] Kratzsch T,Joedicke A.Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.J Cancer Res Clin Oncol2018;144:809-19

[140] Wu Q,Macaulay RJ.Epigenetic activation of TUSC3 sensitizes glioblastoma to temozolomide independent of MGMT promoter methylation status.Int J Mol Sci2023;24:15179 PMCID:PMC10606804

[141] Romani M,Banelli B.Epigenetic targeting of glioblastoma.Front Oncol2018;8:448

[142] Wang J,Li D.Technologies for targeting DNA methylation modifications: basic mechanism and potential application in cancer.Biochim Biophys Acta Rev Cancer2021;1875:188454

[143] Han X,Breuer P.Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma.Neoplasia2023;44:100929 PMCID:PMC10475512

[144] Tong F,Fang ZY.MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.Pharmacol Res2023;187:106606

[145] Yao X,Daniels M.A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.J Clin Invest2003;111:265-73 PMCID:PMC151856

[146] Sharma RK,Vivas-Mejia PE.Targeting non-coding RNA for glioblastoma therapy: the challenge of overcomes the blood-brain barrier.Front Med Technol2021;3:678593 PMCID:PMC8757885

[147] Zhao J,Gartrell RD.Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.Nat Med2019;25:462-9 PMCID:PMC6810613

[148] Bleeker FE,Lamba S.The prognostic IDH1^R132 mutation is associated with reduced NADP⁺-dependent IDH activity in glioblastoma.Acta Neuropathol2010;119:487-94

[149] Lynes JP,Sur HP.Biomarkers for immunotherapy for treatment of glioblastoma.J Immunother Cancer2020;8:e000348 PMCID:PMC7264836

[150] Tancredi A,Bady P.BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.Cell Death Dis2022;13:1037 PMCID:PMC9747918

[151] Singh MM,Venkatarayan A.Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.Neuro Oncol2015;17:1463-73 PMCID:PMC4648298

[152] Sareddy GR,Surapaneni P,Brenner A.Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.Oncogene2017;36:2423-34 PMCID:PMC5526658

[153] Alejo S,Venkata PP.Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.Neuro Oncol2023;25:1249-61

[154] Fang Y,Yu B.LSD1/KDM1A inhibitors in clinical trials: advances and prospects.J Hematol Oncol2019;12:129 PMCID:PMC6894138

[155] Voon HPJ,Lin W.Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma.Nat Commun2018;9:3142 PMCID:PMC6081460

[156] Lee DH,Yoo J.Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.Cell Death Dis2021;12:89 PMCID:PMC7814060

[157] Banelli B,Forlani A.Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.Oncotarget2017;8:34896-910 PMCID:PMC5471020

[158] Romani M,Forlani A,Banelli B.Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of temozolomide-resistant glioblastoma cells.Cancers2019;11:878 PMCID:PMC6627323

[159] Chen R,Zhou Y.The application of histone deacetylases inhibitors in glioblastoma.J Exp Clin Cancer Res2020;39:138 PMCID:PMC7368699

[160] Ellis HP,Powell B,Sottoriva A.Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence.Front Oncol2015;5:251 PMCID:PMC4644939

[161] Kusaczuk M,Bartoszewicz M.Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.Tumour Biol2016;37:931-42 PMCID:PMC4841856

[162] Sawa H,Ohshima Y.Histone deacetylase inhibitors such as sodium butyrate and trichostatin a inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells.Brain Tumor Pathol2002;19:77-81

[163] Funck-Brentano E,Nilsson JA.BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma.Epigenetics2021;16:54-63 PMCID:PMC7889204

[164] Chiao MT,Yang YC,Ko JL.Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells.Autophagy2013;9:1509-26

[165] Alvarez AA,Bushnev S,Sugaya K.The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells.J Mol Neurosci2015;55:7-20

[166] Urdiciain A,Meléndez B,Idoate MA.Tubastatin A, an inhibitor of HDAC6, enhances temozolomideinduced apoptosis and reverses the malignant phenotype of glioblastoma cells.Int J Oncol2019;54:1797-808

[167] Sun X,Lu B.BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network.Nature2023;613:195-202 PMCID:PMC10189659

[168] Schreiber V,Dollé P.Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1.J Biol Chem2002;277:23028-36

[169] Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.Nat Rev Mol Cell Biol2017;18:610-21 PMCID:PMC6591728

[170] Woodhouse BC,Parsons JL.Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks.DNA Repair2008;7:932-40

[171] Sim HW,Khasraw M.PARP inhibitors in glioma: a review of therapeutic opportunities.Cancers2022;14:1003 PMCID:PMC8869934

[172] Smith AJB,Hugo A,Ko EM.Prior authorization for FDA-approved PARP inhibitors in ovarian cancer.Gynecol Oncol Rep2024;52:101335 PMCID:PMC10878851

[173] de Bono J,Fizazi K.Olaparib for metastatic castration-resistant prostate cancer.N Engl J Med2020;382:2091-102

[174] Robson ME,Senkus E.OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Eur J Cancer2023;184:39-47 PMCID:PMC10585240

[175] Messner S,Zhao H.PARP1 ADP-ribosylates lysine residues of the core histone tails.Nucleic Acids Res2010;38:6350-62 PMCID:PMC2965223

[176] Hanna C,Williams K.Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.Neuro Oncol2020;22:1840-50 PMCID:PMC7746945

[177] McDonald MF,Momin EN.Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma.Neuro Oncol2024;26:236-50 PMCID:PMC10836765

[178] Elshaer SS,Fathi D.miRNAs role in glioblastoma pathogenesis and targeted therapy: signaling pathways interplay.Pathol Res Pract2023;246:154511

[179] Mirzaei S,Zabolian A.Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: current status with an emphasis on delivery systems.Life Sci2021;275:119368

[180] Bassot A,Haddad SA.Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma.Cell Death Dis2023;14:630 PMCID:PMC10519979

[181] Straehla JP,Safford HC.A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles.Proc Natl Acad Sci U S A2022;119:e2118697119